Health Discovery Corporation Reaffirms Validation Strategy for Its Prostate Biomarkers

Business Wire, Nov 16, 2005

SAVANNAH, Ga. -- Health Discovery Corporation ("HDC") (OTCBB:HDVY) announced today that it remains on schedule to contract with a third-party diagnostic company in efforts to validate its biomarkers that have the potential to be useful in the diagnosis of clinically significant prostate cancer.

As the Company previously announced, the prostate cancer data was received by HDC when Dr. Thomas Stamey joined the Company's Scientific Advisory Board in July 2004. In April 2005, HDC announced the new biomarker discovery and completion of its initial validation at the Tri-Genome Conference in San Francisco where the prostate cancer biomarker discovery was peer reviewed and accepted for presentation.

Today, two approaches exist for the Company to garner final validation of its prostate cancer biomarkers: (1) HDC can complete an additional validation process itself at an estimated cost of $50,000 by the end of 2005; or, (2) the Company can immediately partner with outside diagnostic companies and validate the biomarkers on their instrumentation in preparation for near-term commercialization.

Allowing a third-party to validate the biomarkers using their own instrumentation will result in minimal out-of-pocket expense by the Company. In addition, and more importantly, HDC made a business decision to suspend additional internal validation efforts and to pursue final validation through the third-party diagnostic companies since its prior internal validation efforts were sufficient to move forward on licensing discussions. The Company is now in discussions with several national and international diagnostic companies to identify possible opportunities, which if successful could lead to licensing revenue in the second quarter 2006.

While the Company believes that its biomarkers will ultimately be validated in light of the Company's previously presented study that demonstrated a 90% accuracy on two completely independent data sets, the Company cannot guarantee when any of the third-party diagnostic companies with whom discussions continue will be able to validate the biomarkers on their instrumentation or whether such validation will occur.

Savannah-based Health Discovery Corporation (OTCBB:HDVY) is uniquely positioned in the field of pattern recognition. Through its broad patent portfolio and the efforts of its recognized scientific team, HDC is focused on commercializing its intellectual property in genomic and proteomic biomarker discovery, medical imaging, diagnostics, and pharmaceutical advancements in personalized medicine. The company's patent-protected technology also has significant application in non-medical fields that require manipulation and analysis of large, complex datasets such as insurance, financial markets, Internet search & spam, and homeland security.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.